Eli Lilly and Company (India) Pvt Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Eli Lilly and Company (India) Pvt Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014217
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eli Lilly and Company (India) Pvt Ltd (Eli Lilly), a subsidiary of Eli Lilly and Company is a drug company that manufactures medicines. The company offers pharmaceutical products for the therapeutic areas such as diabetes, cancer, osteoporosis, cardiovascular disorders and growth-hormone deficiency. Its pharmaceutical products comprise insulin lispros, soluble insulin injection, isophane insulin injection, biphasic isophane insulin injection, pemetrexed disodium, and others. Eli Lilly conducts research and development to develop new products. The company concentrates on personalized medicine. It markets its products through a network of distributors in domestic and overseas markets. Eli Lilly is headquartered in Gurgaon, Haryana, India.

Eli Lilly and Company (India) Pvt Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin 10
Eli Lilly and Company (India) Expands its Agreement With Lupin 11
Licensing Agreements 12
Lupin Enters into Licensing Agreement with Eli Lilly and Company 12
Eli Lilly and Company (India) Pvt Ltd – Key Competitors 13
Eli Lilly and Company (India) Pvt Ltd – Key Employees 14
Eli Lilly and Company (India) Pvt Ltd – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eli Lilly and Company (India) Pvt Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Eli Lilly and Company (India) Pvt Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin 10
Eli Lilly and Company (India) Expands its Agreement With Lupin 11
Lupin Enters into Licensing Agreement with Eli Lilly and Company 12
Eli Lilly and Company (India) Pvt Ltd, Key Competitors 13
Eli Lilly and Company (India) Pvt Ltd, Key Employees 14

★海外企業調査レポート[Eli Lilly and Company (India) Pvt Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boehringer Ingelheim GmbH:企業のM&A・事業提携・投資動向
    Boehringer Ingelheim GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boehringer Ingelheim GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • IOI Corporation Berhad:企業の戦略・SWOT・財務分析
    IOI Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary IOI Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JD Sports Fashion Plc:戦略・SWOT・企業財務分析
    JD Sports Fashion Plc - Strategy, SWOT and Corporate Finance Report Summary JD Sports Fashion Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Nordson Corporation:企業の戦略・SWOT・財務情報
    Nordson Corporation - Strategy, SWOT and Corporate Finance Report Summary Nordson Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Altor BioScience Corp-製薬・医療分野:企業M&A・提携分析
    Summary Altor BioScience Corp (Altor BioScience) is a clinical stage biopharmaceutical company that discovers, develops and commercializes immunotherapeutic products. The company’s pipeline products include ALT-801, ALT-836, and ALT-803. Its technologies are soluble t-cell antigen receptor, inhibito …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Bravura Solutions Limited (BVA):企業の財務・戦略的SWOT分析
    Bravura Solutions Limited (BVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Intracom Holdings S.A. (INTRK):企業の財務・戦略的SWOT分析
    Intracom Holdings S.A. (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • PCI Biotech Holding ASA (PCIB):企業の財務・戦略的SWOT分析
    Summary PCI Biotech Holding ASA (PCI Biotech) is a biopharmaceutical company that focus on development and commercialisation of novel therapies for the treatment of cancer. The company develops therapeutic products based on its proprietary photochemical internalisation technology. Its lead product c …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):企業の財務・戦略的SWOT分析
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • The North West Company Inc. (NWC):企業の財務・戦略的SWOT分析
    The North West Company Inc. (NWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • NovoCure Ltd (NVCR):企業の製品パイプライン分析2018
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …
  • Mercury NZ:戦略・SWOT・企業財務分析
    Mercury NZ - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Wenzel Downhole Tools Ltd:企業の戦略的SWOT分析
    Wenzel Downhole Tools Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • New Zealand Pharmaceuticals Ltd:企業の戦略的SWOT分析
    New Zealand Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • SeraCare Life Sciences, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary SeraCare Life Sciences, Inc. (SeraCare) carries out the discovery, development, manufacture and supply of disease-state specimens and tissues for research and development, processed biological materials, immunoassay reagents and quality control products and technologies. Its major products i …
  • Storebrand ASA:企業のM&A・事業提携・投資動向
    Storebrand ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Storebrand ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報
    Summary Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, c …
  • Pierre & Vacances SA (VAC):企業の財務・戦略的SWOT分析
    Pierre & Vacances SA (VAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆